Journal
MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 23, Issue -, Pages 667-681Publisher
CELL PRESS
DOI: 10.1016/j.omtn.2020.12.024
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [31801115, 61803129]
- China Postdoctoral Science Foundation [2018M631943, 2018M641860]
- China Postdoctoral Science Special Foundation [2019T120280, 2020T130161]
- Hei Long Jiang Postdoctoral Special Foundation [LBHTZ1018]
- Hei Long Jiang Postdoctoral Foundation [LBHZ17110, LBH-Z17218]
- Heilongjiang Provincial Planning Office Key Subjects [GBB1318066]
Ask authors/readers for more resources
Aberrant expression of long non-coding RNAs is associated with altered DNA methylation and histone modifications during carcinogenesis, presenting challenges for cancer studies. This study systematically analyzed epigenetic alterations of lncRNAs in breast cancer subtypes, identifying dysregulated lncRNAs and potential prognostic biomarkers. Epigenetically dysregulated lncRNAs at enhancer elements played a role in subtype-specific biological functions, highlighting their potential prognostic value in breast cancer subtypes.
Aberrant expression of long non-coding RNAs (lncRNA) is associated with altered DNA methylation and histone modifications during carcinogenesis. However, identifying epigenetically dysregulated lncRNAs and characterizing their functional mechanisms in different cancer subtypes are still major challenges for cancer studies. In this study, we systematically analyzed the epigenetic alterations of lncRNAs at important regulatory elements in three breast cancer subtypes. We identified 87, 691, and 1,197 epigenetically dysregulated lncRNAs in luminal, basal, and claudin-low subtypes of breast cancer, respectively. The landscape of epigenetically dysregulated lncRNAs at enhancer elements revealed that epigenetic changes of the majority of lncRNAs occurred in a subtype-specific manner and contributed to subtype-specific biological functions. We identified six acetylation of lysine 27 on histone H3 (H3K27ac)-dysregulated lncRNAs and three DNA methylation-dysregulated lncRNAs (CTC-303L1.2, RP11-738B7.1, and SLC26A4-AS1) as prognostic biomarkers of basal subtype. These lncRNAs were involved in immune response-related biological functions. Treatment of the basal breast cancer cell line MDA-MB-468 with CREBBP/EP300 bromodomain inhibitors downregulated H3K27 acetylation levels and caused a decrease in the expression of five H3K27ac-dysregulated lncRNAs (LINC00393, KB-1836B5.1, RP1-140K8.5, AC005162.1, and AC020916.2) and inhibition of the growth of breast cancer cells. One epigenetically dysregulated lncRNA (LINC01983) and four lncRNA regulators (UCA1, RP11-221J22.2, RP11-221J22.1, and RP1-212P9.3) were identified as prognostic biomarkers of the luminal molecular subtype of breast cancer by controlling the tumor necrosis factor (TNF) signaling pathway, T helper (Th)17 cell differentiation, and T cell migration. Finally, our results highlighted a profound role of enhancer-related H3K27ac-dysregulated lncRNAs, DNA methylation-dysregulated lncRNAs, and lncRNA regulators in breast cancer subtype carcinogenesis and their potential prognostic value.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available